MDxHealth (MDXH) Expected to Announce Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect MDxHealth to post earnings of ($0.21) per share and revenue of $22.67 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

MDxHealth Stock Performance

MDXH stock opened at $1.86 on Monday. The firm has a market cap of $87.72 million, a price-to-earnings ratio of -1.22 and a beta of 1.34. The firm has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.21. MDxHealth has a one year low of $1.55 and a one year high of $3.85. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MDXH. Lake Street Capital began coverage on shares of MDxHealth in a report on Thursday, October 31st. They set a “buy” rating and a $7.00 price objective on the stock. Piper Sandler cut their price objective on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.